Liquid Losartan Composition for Stable Tablet-Bioequivalent Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing losartan formulations, particularly for patients with swallowing difficulties and those with underlying disease conditions, face challenges with bioavailability and stability, and the commercially available liquid preparations are not bioequivalent to tablets, affecting therapeutic efficacy.
Innovation Solution
A stable, liquid pharmaceutical composition of losartan or its pharmaceutically acceptable salts, formulated with specific excipients to ensure bioequivalence to COZAAR® tablets, maintaining stability for at least 12 months and being free of impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If losartan is formulated as tablets for commercial availability, then manufacturing and storage are simplified, but oral administration becomes difficult for patients with swallowing difficulties and bioavailability is reduced
Solution Approach 1:
The patent transforms losartan from solid tablet form to liquid suspension form, fundamentally changing the physical state parameter. This enables easy oral administration via syringe or spoon for patients with swallowing difficulties while maintaining or improving bioavailability through enhanced dissolution and absorption characteristics of the liquid formulation.
Solution Approach 2:
The invention utilizes liquid hydraulic form (suspension) instead of solid form, allowing the medication to flow easily and be administered through liquid delivery systems. This hydraulic approach resolves the contradiction by enabling both ease of administration and reliable bioavailability through improved contact with absorption surfaces in the gastrointestinal tract.
2Ease of operation
If losartan tablets are dispersed with suspending agents and sweeteners to create liquid suspension, then oral administration becomes easier, but stability is reduced to only 4 weeks under refrigerated conditions
Solution Approach 1:
The patent employs a composite formulation system combining losartan with specific suspending agents, sweeteners, and stabilizers in optimized proportions. This composite approach creates a synergistic effect where each component contributes to both the ease of administration and the extended stability, achieving 12 months shelf life while maintaining liquid suspension properties for easy oral delivery.
Solution Approach 2:
The formulation includes stabilizers and preservatives added beforehand to prevent degradation and maintain stability over extended periods. This prior cushioning against chemical and physical degradation allows the liquid suspension to remain stable for 12 months without refrigeration, resolving the contradiction between ease of administration and formulation stability.
3Ease of operation
If compounded liquid preparations are made for patient use, then administration becomes easier for difficult patients, but bioequivalence to tablets is not achieved, affecting therapeutic efficacy
Solution Approach 1:
The patent carefully controls critical parameters including pH (adjusted to optimal range for losartan stability and absorption), particle size distribution of suspended losartan, and concentration ratios of active ingredient to excipients. These parameter optimizations ensure that the liquid suspension achieves bioequivalence to tablets by controlling dissolution rate and absorption characteristics, while simultaneously providing ease of administration through liquid form.
Solution Approach 2:
The invention replaces the mechanical swallowing process required for tablets with a liquid suspension that can be easily delivered via syringe or spoon. This substitution maintains therapeutic efficacy by ensuring complete delivery of the dose without the mechanical barrier of swallowing, while the controlled formulation parameters guarantee bioequivalence through consistent absorption kinetics.
Data Source
AI summary
The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.